New drugs and targeted treatments in Hodgkin's lymphoma

Mariano Provencio; Antonio Sánchez; Margarita Sánchez-Beato

doi:10.1016/j.ctrv.2013.09.005

New drugs and targeted treatments in Hodgkin's lymphoma

Cancer Treat Rev. 2014 Apr;40(3):457-64. doi: 10.1016/j.ctrv.2013.09.005. Epub 2013 Sep 20.

Authors

Mariano Provencio¹, Antonio Sánchez², Margarita Sánchez-Beato²

Affiliations

¹ Medical Oncology Service, Onco-hematology Research Unit, Instituto de Investigación Sanitaria Puerta de Hierro, Hospital Universitario Puerta de Hierro-Majadahonda, Spain. Electronic address: mprovenciop@gmail.com.
² Medical Oncology Service, Onco-hematology Research Unit, Instituto de Investigación Sanitaria Puerta de Hierro, Hospital Universitario Puerta de Hierro-Majadahonda, Spain.

PMID: 24095205
DOI: 10.1016/j.ctrv.2013.09.005

Abstract

New drugs are being developed in recent years that may change the handling of relapsed and refractory Hodgkin's lymphoma patients. Brentuximab vedotin treatment has already been approved by the FDA; and other drugs are promising, such as histone deacetylase inhibitors, bendamustine, lenalidomide and m-TOR inhibitors.

Keywords: Bendamustine; Brentuximab vedotin; Deacetylase inhibitors; Hodgkin’s lymphoma; Lenalidomide; Target treatments; m-TOR inhibitors.

Publication types

Review

MeSH terms

Animals
Antineoplastic Agents / therapeutic use*
Drugs, Investigational / therapeutic use
Hodgkin Disease / therapy*
Humans
Molecular Targeted Therapy / methods*
Treatment Outcome

Substances

Antineoplastic Agents
Drugs, Investigational